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Abstract 
This study evaluates trends in hepatitis C virus (HCV)-related hepatocellular carcinoma 
(HCC) incidence and survival in three settings, prior to introduction of direct-acting antiviral 
(DAA) therapies. HCV notifications from British Columbia (BC), Canada, New South Wales 
(NSW), Australia, and Scotland (1995-2011/2012/2013, respectively) were linked to HCC 
diagnosis data via hospital admissions (2001-2012/2013/2014, respectively), and mortality 
(1995-2013/2014/2015, respectively). Age-standardised HCC incidence rates were evaluated, 
associated factors were assessed using Cox regression, and median survival time after HCC 
diagnosis was calculated. Among 58,487, 84,529, and 31,924 people with HCV in BC, NSW, 
and Scotland, 734 (1.3%), 1,045 (1.2%), and 345 (1.1%) had an HCC diagnosis. Since mid-
2000s, HCC diagnosis numbers increased in all jurisdictions.  Age-standardised HCC 
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incidence rates remained stable in BC and Scotland, and increased in NSW. The strongest 
predictor of HCC diagnosis was older age [birth <1945, aHR in BC 5.74, 95% CI 4.84, 6.82; 
NSW 9.26, 95% CI 7.93, 10.82; Scotland 12.55, 95% CI 9.19, 17.15]. Median survival after 
HCC diagnosis remained stable in BC (0.8 years in 2001-2006 and 2007-2011) and NSW 
(0.9 years in 2001-2006 and 2007-2013), and improved in Scotland (0.7 years in 2001-2006 
to 1.5 years in 2007-2014).  Across the settings, HCC burden increased, individual-level risk 
of HCC remained stable or increased, and HCC survival remained extremely low. These 
findings highlight the minimal impact of HCC prevention and management strategies during 
the interferon-based HCV treatment era, and form the basis for evaluating the impact of DAA 
therapy in the coming years.  
 
Keywords: HCV; liver disease; primary liver cancer; population-based; data linkage 
Globally, in 2012, primary liver cancer was the fifth most common cancer in men, and the 
ninth in women (1). The alarmingly poor prognosis enhances the burden of primary liver 
cancer; the second leading cause of cancer mortality in 2012 (1). In high-income countries, an 
increasing proportion of the most common type of primary liver cancer, hepatocellular 
carcinoma (HCC), is attributed to hepatitis C virus (HCV) infection (1). Opportunities to 
increase the uptake of antiviral therapy offer promise for reducing the current and future HCC 
burden (2-4). However, evaluating the success of treatment programs depends on having 
solid baseline data and the ability to monitor population-level HCC diagnosis trends, risk 
factors, and prognosis in different settings over time. 
 
The rising burden of HCV-related HCC can be explained by the natural history of HCV 
infection, the contribution of risk factors for liver disease progression such alcohol-use 
disorder, and negligible population-level impact of interferon-based treatments on HCV-
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related liver disease (5). Given the advent of interferon-free direct-acting antiviral (DAA) 
therapies, many future cases of HCV-related HCC diagnosis could be prevented if greater 
numbers of people undergo treatment (6). Several barriers remain to increase access to HCV 
treatment programs, including the high cost of new regimens and treatment capacity in most 
settings (7). Further, potential impact of improved therapies on the risk of HCC recurrence 
and HCC survival are not well understood (8, 9). As a result, the projected burden of HCC in 
the DAA era remains unclear, highlighting the need for ongoing international surveillance of 
HCC to inform and improve public health policy and clinical practice over the next decade.        
 
Globally, British Columbia (BC), Canada, New South Wales (NSW), Australia, and Scotland 
are among the few settings with established population-based surveillance systems that 
enable monitoring people with HCV infection by linkage between HCV diagnosis databases 
and hospitalisation records. The aim of this study was to assess trends in population-level 
HCC diagnosis rates, contribution of risk factors to HCC diagnosis, and survival after HCC 
diagnosis among people with HCV infection.  
 
Materials and methods 
Data sources and record linkages  
British Columbia, Canada 
The British Columbia Hepatitis Testers Cohort (BC-HTC) holds records of all individuals 
tested for HCV, HBV, and HIV at the BC Centre for Disease Control Public Health 
Laboratory, since 1992, or reported as a confirmed case of HCV, HBV, and HIV/AIDS, since 
1990 (10). At the end of each episode of admission, all BC hospitals submit their 
hospitalisation records (including demographic, administrative, and diagnosis information) 
directly to the Canadian Institute of Health information for inclusion in the Discharge 
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Abstracts Database, since 1985 (11). All hospitalisation records are coded using the 10
th
 
revision of the Classification of Diseases and Related Health Problems (ICD-10), since 2001. 
Information on all deaths registered in BC are held by the BC Vital Statistics Agency, since 
1985 (12). Using personal health numbers assigned to each individual in BC, BC-HTC 
records were deterministically linked to hospitalisation and mortality datasets. Record 
linkages were carried out by the BC Centre for Disease Control and BC Ministry of Health 
(10). 
 
New South Wales, Australia 
The NSW Notifiable Conditions Information Management System (NCIMS) holds records of 
all individual with positive HCV and HBV serology tests, notified of diagnoses via 
mandatory notification procedures, since 1991 (13). National HIV Registry holds records of 
all notifications of HIV infection, since 1985 (14). NSW Admitted Patient Data Collection 
covers all inpatient admissions from all hospitals in NSW, since 2001 (13). Each 
hospitalisation record includes demographic, administrative and diagnosis information coded 
at discharge according to ICD-10 (13). Information on all deaths registered in NSW is held 
by the Registry of Births, Deaths and Marriages, since 1993 (13). Using demographic details 
(including full name, gender, date of birth, and address), probabilistic linkages of records 
between the NCIMS, hospitalisation, and mortality datasets were undertaken by the NSW 
Centre for Health Record Linkage (13). 
 
Scotland 
Health Protection Scotland holds records of all individual with positive HCV and HBV 
serology tests since 1991 (15). Notifications of HIV diagnosis have been recorded since 1981 
(15). Hospital admission data are available from the Scottish Morbidity Records, comprising 
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all Scottish hospitalisations since 1981, including demographic, administrative and diagnosis 
information coded at separation (according to ICD-10 since 1996) (15). Information on all 
deaths registered in Scotland is held by the National Records of Scotland, since 1980 (16). 
Using unique identifiers and demographic details (including forename initial, surname 
Soundex, gender, date of birth, and postcode district of residence), a combination of 
deterministic and probabilistic linkages of records between the HCV notifications, 
hospitalisation, and mortality datasets were undertaken by Information Services Division 
Scotland (15). 
 
Study period 
HCV notifications were extracted for the study period between 1 January 1995 and 31 
December 2011 (BC), 2012 (NSW), and 2013 (Scotland) and linked hospitalisation records 
were extracted for the study period between 1 January 2001 and 31 December 2012 (BC), 
2013 (NSW), and 2014 (Scotland). In each setting, linked mortality records were extracted 
for the study period between 1 January 1995 and six months after the latest hospitalisation 
record. 
 
 
Study outcome 
The primary outcome of interest was first-time hospitalisation due to HCC. A hospital 
discharge diagnosis code was used to define HCC diagnosis; coded in either the principal or 
secondary diagnosis fields of a linked inpatient hospital record (ICD-10 code C22.0). 
Hereafter, a first-time HCC hospital admission is referred to as HCC diagnosis.  
 
Exclusion criteria 
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Exclusion criteria were applied as follows: records where date of birth was missing, and 
records where the date of HCV notification occurred more than three months after date of 
death (post-mortem notification), or prior to January 1, 1995. 
 
Statistical analysis 
Among people with an HCV notification in each setting, trends in HCC diagnosis numbers 
were evaluated. Age-standardised HCC incidence rates [per 100 person-years (PY)], and 
corresponding 95% CIs were calculated using the Poisson distribution. The European 
Standard Population 2013 was used for standardisation. The strength of association between 
risk factors and HCC diagnosis was assessed using unadjusted and adjusted Cox proportional 
hazard regression analyses; covariates included birth cohort, gender, year of HCV 
notification, HBV and HIV co-infection, and alcohol-use disorder. Among people with an 
HCC diagnosis, median survival time after HCC diagnosis was evaluated. 
 
Alcohol-use disorder is a standard term used to define continued drinking despite adverse 
mental and physical consequences (17). Liver-related consequences of alcohol use are not 
included in the definition of alcohol-use disorder (17). Hospital discharge diagnosis codes 
(ICD-10) were used to define alcohol-use disorder; coded in either the principal or a 
secondary diagnosis field of a linked inpatient hospital record. The set of relevant codes 
included: alcohol-induced Pseudo-Cushing's syndrome (E24.4), mental and behavioural 
disorders due to use of alcohol (F10), degeneration of nervous system due to alcohol (G31.2), 
alcoholic polyneuropathy (G62.1), alcoholic cardiomyopathy (I42.6), alcoholic myopathy 
(G72.1), alcohol rehabilitation (Z50.2), and alcohol abuse counselling and surveillance 
(Z71.4).  Hereafter, having a history of at least one alcohol-use disorder-related hospital 
admission is referred to as alcohol-use disorder. Alcohol-use disorder was not included as a 
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time-dependent variable in Cox proportional regression analyses, given that it is considered 
to be an indicator of a long-standing condition. To calculate age-standardised HCC incidence 
rates and assess factors associated with HCC diagnosis, person-time at risk was defined to 
start six months post the date of HCV notification (but was left-censored to 1 January 2001 if 
HCV notification was before this date), and to end at whichever occurred first; death, or end 
of follow-up, assigned by year. To calculate median survival time, observation time was 
defined to start on the date of HCC diagnosis, and to end at whichever occurred first; death, 
or end of follow-up. Statistical analyses were carried out in STATA versions 12 and 13 or 
SAS version 9.4. 
 
Results 
Study participants  
There were 58,487 people with an HCV notification in BC, 84,529 in NSW, and 31,924 in 
Scotland (total n=174,940). A higher proportion of people from BC (61%) were born during 
1945-64 compared to NSW (41%) and Scotland (24%) (Table 1). Across the three settings, 
63-65% were male, 29-49% had an HCV notification during 1995-2000, and 18-27% had 
alcohol-use disorder (Table 1). The proportion of people with an HCV notification who 
developed HCC was very similar across the three settings: 1.3% (n=734) in BC, 1.2% 
(n=1,045) in NSW and 1.1% (n=345) in Scotland. Across the three settings, those with an 
HCC diagnosis were more likely to be born during 1945-1964, and male. Among people with 
an HCC diagnosis, the proportion of individuals with alcohol-use disorder ranged from 17% 
in BC, to 23% in NSW and 27% in Scotland (Table 1).  
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Age at HCC diagnosis 
The age distribution at HCC diagnosis varied across settings. In BC, NSW, and Scotland, 
those aged 50 years or older at the time of HCC diagnosis comprised 89%, 66%, and 77% of 
the population with an HCC diagnosis in the mid-2000s, respectively. In early 2010s, people 
in the same age group comprised 95%, 84%, and 87% of the population with an HCC 
diagnosis in BC, NSW and Scotland, respectively (Figure 1).  
 
HCC diagnosis numbers and rates 
Compared to 2004, HCC diagnosis numbers increased in all jurisdictions [38 to 92 in 2011 in 
BC (P<0.001), 47 to 167 in 2012 in NSW (P<0.001), and 12 to 52 in 2013 in Scotland 
(P<0.001)] (Figure 2). Since 2004, age-standardised HCC incidence rates remained stable in 
BC (0.02 to 0.02 per 100 PY in 2011, P=0.774) and Scotland (0.10 to 0.11 per 100 PY in 
2013, P=0.995). However, in NSW, age-standardised HCC incidence rates increased from 
0.10 in 2004 to 0.15 per 100 PY in 2012, P=0.005 (Figure 2).  
 
Factors associated with HCC diagnosis  
In unadjusted analyses across the three settings, HCC diagnosis was associated with older 
age, male gender, and HCV notification year ≥2007. In unadjusted analyses, HBV co-
infection was associated with HCC diagnosis in NSW and HIV co-infection was associated 
with reduced likelihood of HCC diagnosis in BC (Supplementary Table 1). In adjusted 
analysis, older age (birth before 1945) was the strongest predictor of HCC diagnosis [adjusted 
hazard ratio (aHR) in BC 5.74, 95% CI 4.84, 6.82; in NSW 9.26, 95% CI 7.93, 10.82; and in 
Scotland 12.55, 95% CI 9.19, 17.15], followed by male gender in BC (aHR 2.70, 95% CI 
2.21, 3.31), and HCV notification year ≥2007 in NSW (aHR 3.71, 95% CI 2.88, 4.78), and 
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Scotland (aHR 3.00, 95% CI 1.97, 4.55) (Table 2). The association between HCC diagnosis 
and more recent HCV notification years was driven by older age (Supplementary Table 2). 
 
Survival after HCC diagnosis  
Median survival time after HCC diagnosis remained stable during the study period in BC (0.8 
years in 2001-2006 and 2007-2011) and NSW (0.9 years in 2001-2006 and 2007-2013). 
However, median survival after HCC diagnosis improved in Scotland, from 0.7 years in 
2001-2006 to 1.5 years in 2007-2014. Across the three settings, median survival after HCC 
diagnosis was highest in Scotland (1.3 years, 95% CI 0.99, 1.97) (Table 3). 
 
Discussion 
The burden of HCV-related HCC continued to increase in BC, Canada; NSW, Australia; and 
Scotland, despite availability of curative interferon-based treatment that had limited uptake 
and effectiveness. Since 2004, HCC diagnosis numbers increased significantly in all settings, 
while age-standardised HCC incidence rates remained relatively stable in BC and Scotland, 
and increased in NSW. While linkage to HCV treatment data was not possible in all settings, 
these findings suggest interferon-based antiviral treatment programs have had no impact on 
the population-level burden and individual-level risk of HCC. During the study period, 
interferon-based HCV treatment uptake and outcomes remained suboptimal across the 
settings, particularly among people with advanced liver disease (2-4). Access to highly 
effective interferon-free DAA regimens is now provided in the three countries and expected 
to prevent end stage liver disease including HCC. However, there is a need to monitor 
population level impact of treatment scale up on end stage liver disease.  The availability of 
data on mandatory HCV notifications and the capacity for regular linkage to other 
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administrative databases provides the opportunity for ongoing evaluation and comparison of 
HCV public health strategies in the DAA era between BC, NSW, and Scotland. 
 
Survival following HCC diagnosis remained extremely poor across the three settings; 
however, median survival increased in recent years in Scotland. The apparent improvement is 
consistent with data from the Scottish Cancer Registry and may result from enhanced HCC 
screening practices and receipt of curative HCC procedures, or may reflect lead time bias 
(18). Nevertheless, in the mid-2000s, the 3-year and 5-year HCC survival were only 11.8% 
and 4.4% among Scottish men, respectively (18). HCC outcomes among people with HCV 
infection are influenced by contributing factors including antiviral treatment uptake. A 
systematic review and meta-analysis of interferon-based studies demonstrated a 77% 
reduction in HCC risk among patients with cirrhosis who achieved sustained virological 
response (SVR) (19). However, SVR rates were sub-optimal in patients with compensated 
cirrhosis and interferon-based therapy was not utilised in those with decompensated cirrhosis. 
DAA regimens have been shown to be highly effective among people with compensated and 
decompensated cirrhosis, leading to remarkable short-term liver function improvements and 
even delisting for liver transplantation (20). Yet, contrasting reports of HCC occurrence and 
reoccurrence risk after DAA-induced viral clearance add to current uncertainties on impact of 
DAA treatments on HCC risk (8, 9). Older age is a key risk factor for HCC risk among 
people with cirrhosis, even following SVR, therefore the apparent higher risk of HCC 
following SVR in the DAA era is likely due to confounding by older age, and also shorter 
follow-up in DAA era studies (21-24). Further evaluation of the issue of HCC risk post-SVR 
in the DAA era should be possible in the near future in BC, NSW, and Scotland, as access to 
government funded DAA treatments improve uptake and availability of integrated 
surveillance datasets to monitor HCC trends.  
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Other factors influencing HCC outcomes include appropriate HCC screening and timely 
HCC treatment initiation. The last decade has witnessed developments in the clinical 
management of HCC (25); however, these advances have not been translated into major 
improvements in HCC outcomes at the population-level. HCC screening and diagnosis 
among people with cirrhosis remain underutilised, given barriers at the patient-, provider- and 
system-levels, and lack of high-quality evidence in favour of screening (26, 27). In the 
absence of data from randomised trials, however, observational studies provide evidence 
linking HCC screening with improved outcomes (28, 29). Given the rising burden of HCC, 
this evidence should be used to enhance the patient and provider knowledge of HCC risk 
factors, screening and treatment options, and improve provision of care through 
multidisciplinary teams (30). 
Across the three settings, older age was the strongest predictor of HCC diagnosis. Other 
factors associated with HCC diagnosis included alcohol-use disorder, male gender, and 
HBV/HCV/HIV co-infection. These well-documented risk factors for liver disease 
progression and tumour development could characterise high-risk populations who might 
benefit from enhanced prevention strategies (23, 24). Our findings also highlight the 
implications of the multifactorial etiology of HCC. Due to its complex nature and association 
with advanced liver disease, HCC prevention and management requires close collaboration 
among a multidisciplinary team of healthcare professionals (25, 31-33). Given availability of 
curative procedures, timely diagnosis, selection of a therapeutic intervention, and referral to 
the appropriate specialist are critical steps for delivery of optimal HCC care. 
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This study has several limitations. First, to improve the accuracy of trends in HCC diagnosis 
numbers and age-standardised rates across the settings, these data were displayed and 
analysed since 2004. In Scotland, the pre-2004 HCC trends were overestimated, given low 
HCV diagnosis rates during the early-mid 2000s (62% undiagnosed in 2006) (34). Second, 
two factors might have contributed to lower age-standardised HCC rates in BC, including 
older age distribution in this setting (compared to the European standard population), and 
residual confounding. Third, the lack of clinical details on HCC screening, HCC stage of 
diagnosis, and HCC clinical management strategies is a clear limitation. Therefore, analysis 
of HCC survival time could not be adequately adjusted for lead-time bias. Fourth, using 
administrative data for defining alcohol-use disorder has clear limitations. The current study 
has potential under-ascertainment of alcohol-use disorder, with potential overestimation of 
the impact on HCC risk if more severe forms of alcohol-use disorder were more likely to be 
classified (35, 36). Fifth, HCV diagnosis for surveillance reporting is generally based on anti-
HCV antibody detection and does not require HCV RNA confirmation. Thus, an estimated 
25% of HCV notifications would have undergone spontaneous HCV clearance. These 
limitations should, however, not have a major impact on the study findings, given the 
surveillance definition and systems in the three settings have been stable throughout the study 
period. 
 
In conclusion, this international comparison of population-level data provides evidence for 
the rising burden of HCV-related advanced liver disease in BC, NSW, and Scotland, 
highlighting the combined impact of ageing, suboptimal HCV treatment efficacy and uptake, 
and low levels of HCC screening and early diagnosis. Over the coming years, the population-
level-burden and individual-level risk of HCC would be expected to decline, given the 
potential impact of well tolerated and effective DAA treatments. In addition, enhanced HCC 
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screening could enable early diagnosis and better management options. Use of administrative 
databases for surveillance, particularly with the addition of individual-level antiviral 
treatment data will be a valuable tool for evaluation and monitoring trends of HCV and HCC 
burden in relation to public health intervention strategies across the three settings.  
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Table 1. Demographic characteristics among people with an HCV notification in BC, 
NSW, and Scotland, since 1995 
 BC, Canada NSW, Australia Scotland 
 
HCV notifications 
1995-2011 
HCV notifications 
1995-2012 
HCV notifications 
1995-2013 
  All  HCCα  All  HCCα  All  HCCα  
Characteristics, n % n=58,487 % n=734 % n=84,529 % n=1,045 % n=31,924 % n=345 % 
Birth cohort             
    ≥1965 17,397 30 11 2 45,298 54 50 5 22,889 72 16 5 
    1945-1964 35,616 61 504 69 34,518 41 732 70 8,051 25 264 77 
    <1945 5,474 9 219 30 4,713 6 263 25 984 3 65 19 
Maleβ 38,212 65 600 82 53,146 63 826 79 21,369 65 278 81 
Year of HCV 
notification 
            
     1995-2000 28,517 49 367 50 39,043 46 490 45 9,141 29 96 28 
     2001-2006 18,339 31 257 35 26,754 32 345 33 9,645 30 120 35 
     ≥2007 11,631 20 110 15 18,732 22 210 20 13,138 41 129 37 
Co-infection status             
     None 51,381 88 661 90 80, 112 95 971 93 30,653 96 329 95 
     HBV 3,255 6 52 7 3,467 4 68 7 587 2 10 3 
     HIV 2,910 5 11 2 888 1 5 <1 645 2 5 1 
     HBV/HIV 941 2 10 1 62 <1 1 <1 39 <1 1 <1 
Alcohol-use disorderγ  11,078 19 122 17 14,797 18 240 23 8,737 27 93 27 
αHCC diagnosis during 2001-2012 in BC, 2001-2013 in NSW, and 2001-2014 in Scotland, βamong people with 
available information, γamong people with an HCC diagnosis, alcohol-use disorder was included if occurred 
prior to HCC diagnosis 
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Table 2. Adjusted analysis of factors associated with HCC diagnosis among people with an HCV notification in BC, NSW, and Scotland, 
since 1995 
 
BC, Canada 
HCV notification, 1995-2011 
n=56,640 
NSW, Australia 
HCV notification, 1995-2011 
n=83,061 
Scotland 
HCV notification, 1995-2013 
n=31,132 
Characteristics, n % 
HCCα 
n=646 
aHRβ 95% CI P 
HCCα 
n=908 
aHRβ 95% CI P 
HCCα 
n=275 
aHRβ 95% CI P 
Birth cohort              
    ≥1945 459 1.00 - - 678 1.00 - - 223 1.00 - - 
    <1945 187 5.74 4.84, 6.82 <0.001 230 9.26 7.93, 10.82 <0.001 52 12.55 9.19, 17.15 <0.001 
Gender             
    Female 116 1.00 - - 183 1.00 - - 62 1.00 - - 
    Male 530 2.70 2.21, 3.31 <0.001 725 2.59 2.20, 3.05 <0.001 213 1.91 1.44, 2.55 <0.001 
Year of HCV notification             
     1995-2000 366 1.00 - - 453 1.00 - - 86 1.00 - - 
     2001-2006 219 1.48 1.24, 1.76 <0.001 315 1.70 1.44, 2.02 <0.001 101 1.69 1.20, 2.28 0.003 
     ≥2007 61 2.21 1.64, 2.98 <0.001 140 3.71 2.88, 4.78 <0.001 88 3.00 1.97, 4.55 <0.001 
Co-infection statusδ             
      None 577 1.00 - - 848 1.00 _ _ 262 - - - 
      HBV 48 1.30 0.96, 1.74 0.085 54 1.46 1.11, 1.92 0.007 7 - - - 
      HIV 11 0.42 0.23, 0.77 0.005 5 0.62 0.26, 1.49 0.283 5 - - - 
      HBV/HIV 10 1.24 0.66, 2.33 0.501 1 1.81 0.25, 12.84 0.555 1 - - - 
Alcohol-use disorderε             
      No 532 1.00 - - 683 1.00 - - 195 1.00 - - 
      Yes 114 1.02 0.83, 1.25 0.829 225 2.05 1.75, 2.39 <0.001 80 1.40 1.08, 1.83 0.013 
αHCC diagnosis during 2001-2012 in BC, 2001-2013 in NSW, and 2001-2014 in Scotland, βadjusted hazard ratio, γbirth cohort categories ≥1965 and 1945-1964 were 
combined, given small numbers of HCC diagnosis among those born in or after 1965, δ not included in all adjusted models, given small numbers with an HCC diagnosis 
and/or P value >0.2 in unadjusted analyses, εamong people with an HCC diagnosis, alcohol-use disorder was included if occurred prior to HCC diagnosis 
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Table 3. Median survival after HCC diagnosis among people with an HCV notification in BC, NSW, and Scotland, since 1995 
 BC, Canada 
HCC diagnosis, 2001-2012 
n=646 
NSW, Australia 
HCC diagnosis, 2001-2013 
n=908 
Scotland 
HCC diagnosis, 2001-2014 
n=275 
Study period 
Subjects, 
n 
Median survival, 
years 
95% CI 
Subjects, 
n 
Median survival, 
years 
95% CI Subjects, n 
Median survival, 
years 
95% CI 
 2001-2006 191 0.8 0.57, 1.06 225 0.9 0.57, 1.33 52 0.7 0.32, 1.25 
 ≥2007 372 0.8 0.66, 1.00 765 0.9 0.73, 1.14 245 1.5 1.04, 2.41 
Total 563 0.8 0.68, 0.98 908 0.9 0.75, 1.10 275 1.3 0.99, 1.97 
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Figure 1. Age at HCC diagnosis among people with an HCV notification in BC, NSW, 
and Scotland, since 1995  
 
Figure 2. Temporal trends in HCC diagnosis numbers and age standardised incidence 
rates among people with an HCV notification in BC, NSW, and Scotland, since 1995  
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